Related Experiment Video

Updated: Apr 4, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Ceftobiprole for the treatment of pneumonia: a European perspective

Adamantia Liapikou1, Catia Cillóniz2, Antonio Torres2

  • 16th Respiratory Department, Sotiria Chest Diseases Hospital, Athens, Greece.

Drug Design, Development and Therapy
|August 29, 2015
PubMed

Insights

Ceftobiprole, a new cephalosporin, effectively treats hospital-acquired and community-acquired pneumonia. While generally safe and non-inferior to other treatments, it showed lower efficacy in mechanically ventilated patients.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Ceftobiprole is a novel, broad-spectrum parenteral cephalosporin.
  • It demonstrates significant in vitro activity against key Gram-positive pathogens like MRSA and penicillin-resistant S. pneumoniae.
  • It also targets Gram-negative pathogens implicated in hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP).

Purpose of the Study:

  • To evaluate the efficacy and safety of ceftobiprole in treating CAP and HAP.
  • To compare ceftobiprole's clinical outcomes against established treatments.

Main Methods:

  • Two large-scale pivotal studies were conducted.
  • Ceftobiprole was compared to ceftriaxone (with or without linezolid) for CAP.
  • Ceftobiprole was compared to ceftazidime for HAP.

Main Results:

  • Ceftobiprole demonstrated non-inferiority in both CAP and HAP treatment groups.
  • Clinical cure rates for CAP were 86.6% (ceftobiprole) vs. 87.4% (comparator).
  • Clinical cure rates for HAP were 77% (ceftobiprole) vs. 76% (comparator).
  • However, ceftobiprole was found to be inferior in the subgroup of patients requiring mechanical ventilation.
  • The safety profile was comparable to comparators, with headache and gastrointestinal upset being the most common adverse events.

Conclusions:

  • Ceftobiprole is the first cephalosporin monotherapy approved in the EU for both CAP and HAP (excluding VAP).
  • It offers a valuable treatment option for these conditions, with a favorable safety profile.
  • Further investigation is warranted for its use in mechanically ventilated patients.
Keywords:
antibiotic resistancecephalosporinscommunity-acquired pneumoniahospital-acquired pneumoniamethicillin-resistant staphylococci

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.9K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
715
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
718
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
47